Hospital
Mcalester Regional Health Center Authority
Mcalester Regional Health Center Authority was paid $10.12M by Medicaid between Jan 2018 and Nov 2024, across 151 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoMCALESTER REGIONAL HEALTH CENTER AUTHORITY
MCALESTER, OK 74501
MCALESTER, OK 74501
33aNPI1316940034assigned 05/27/2005
33bProvider typeRural Acute Care Hospital
28Total paid$10.12M
24GClaims170,329
24DCodes billed151
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Oklahoma
Rank by total paid#2 of 10
Median peer was paid$1.46M
This provider vs. median6.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,582 | $1.93M | |
| 2019 | 24,538 | $1.44M | |
| 2020 | 15,478 | $976K | |
| 2021 | 15,651 | $1.18M | |
| 2022 | 29,036 | $1.66M | |
| 2023 | 35,113 | $1.72M | |
| 2024incomplete | 18,931 | $1.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 22,699 | 20,528 | $2.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 14,417 | 13,066 | $2.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10.0% | 3,974 | 3,766 | $1.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.6% | 11,535 | 10,460 | $873K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.8% | 4,863 | 4,793 | $582K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.9% | 1,539 | 550 | $197K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 3,031 | 2,943 | $132K |
| D9999 | Unspecified adjunctive procedure, by report | 1.2% | 127 | 127 | $125K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,033 | 7,932 | $95K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,620 | 13,077 | $91K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,867 | 15,099 | $83K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 1,648 | 1,150 | $78K |
139 more codes
| 80053 | Comprehensive metabolic panel | <1% | 8,561 | $77K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 680 | $74K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 989 | $71K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 559 | $56K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 26 | $46K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 778 | $42K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 207 | $39K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 697 | $38K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 201 | $33K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 593 | $31K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 276 | $29K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 631 | $28K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 632 | $27K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 754 | $25K |
| 59426 | <1% | 28 | $25K | |
| 87631 | <1% | 194 | $25K | |
| 81001 | <1% | 8,318 | $24K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 174 | $23K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 632 | $23K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,014 | $22K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 449 | $21K |
| 87400 | <1% | 1,421 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 334 | $19K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 226 | $19K |
| 73560 | <1% | 966 | $18K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 66 | $17K |
| 84484 | <1% | 1,522 | $17K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 488 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,092 | $16K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 450 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 429 | $13K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 281 | $13K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 34 | $13K |
| 73565 | <1% | 517 | $13K | |
| 84703 | <1% | 1,816 | $12K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 384 | $12K |
| 88312 | <1% | 99 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 379 | $12K |
| 83880 | <1% | 359 | $12K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 786 | $11K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 47 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 75 | $10K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 128 | $10K |
| 76801 | <1% | 161 | $9K | |
| 83735 | <1% | 1,341 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 505 | $7K |
| 59425 | <1% | 15 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 495 | $6K |
| 73110 | <1% | 268 | $6K | |
| 83690 | <1% | 1,021 | $6K | |
| 87807 | <1% | 413 | $5K | |
| 80061 | Lipid panel | <1% | 420 | $5K |
| 83605 | <1% | 441 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 300 | $4K |
| 82677 | <1% | 193 | $4K | |
| 81015 | <1% | 1,511 | $4K | |
| 83615 | <1% | 747 | $4K | |
| 73562 | <1% | 213 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 197 | $4K |
| 99223 | Prolong inpt eval add15 m | <1% | 43 | $4K |
| 87581 | <1% | 125 | $4K | |
| 86850 | <1% | 459 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 742 | $4K |
| 84702 | <1% | 269 | $4K | |
| 86787 | <1% | 315 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 504 | $4K |
| 86762 | <1% | 272 | $3K | |
| 87653 | <1% | 112 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 44 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 417 | $3K |
| 82105 | <1% | 194 | $3K | |
| 87340 | <1% | 321 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 41 | $3K |
| 81003 | <1% | 1,221 | $3K | |
| 84100 | <1% | 676 | $3K | |
| 87070 | <1% | 343 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,079 | $3K |
| 86336 | <1% | 193 | $3K | |
| 84550 | <1% | 676 | $3K | |
| 81000 | <1% | 825 | $3K | |
| 73630 | <1% | 124 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 56 | $2K |
| 87797 | <1% | 101 | $2K | |
| 87486 | <1% | 75 | $2K | |
| 86735 | <1% | 181 | $2K | |
| 93016 | <1% | 145 | $2K | |
| 86780 | <1% | 153 | $2K | |
| 93018 | <1% | 186 | $2K | |
| 86803 | <1% | 139 | $2K | |
| 86765 | <1% | 142 | $2K | |
| 31575 | <1% | 18 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 14 | $1K |
| 73030 | <1% | 90 | $1K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $1K |
| 86901 | <1% | 490 | $1K | |
| 86900 | <1% | 490 | $1K | |
| 93000 | <1% | 134 | $1K | |
| 87430 | <1% | 88 | $1K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 37 | $1K |
| 88342 | <1% | 14 | $1K | |
| 86703 | <1% | 124 | $1K | |
| 93017 | <1% | 36 | $1K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 47 | $941.71 |
| 87081 | <1% | 148 | $931.16 | |
| 85027 | <1% | 162 | $871.81 | |
| 86592 | <1% | 185 | $642.20 | |
| 72040 | <1% | 37 | $640.66 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $618.78 |
| 99221 | <1% | 12 | $615.28 | |
| 82950 | <1% | 133 | $584.48 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $580.62 |
| 84145 | <1% | 16 | $363.15 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 231 | $221.34 |
| 82150 | <1% | 28 | $177.04 | |
| 82550 | <1% | 28 | $170.61 | |
| 94060 | <1% | 18 | $157.77 | |
| 83655 | <1% | 13 | $140.01 | |
| 73610 | <1% | 13 | $139.77 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,335 | $127.49 |
| 85730 | <1% | 16 | $74.90 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 289 | $66.20 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 20 | $65.57 |
| 85610 | <1% | 19 | $61.12 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 39 | $30.20 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 203 | $1.12 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 504 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,384 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 241 | $0.00 |
| J3490 | Unclassified drugs | 0% | 103 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 153 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 71 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 77 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 63 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 12 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 36 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 24 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 14 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPERRY, CHERYL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Perry Physical Therapy | Jackson, OH | $194K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.